Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| O-Tolylamine SCHEMBL7744406 | 0.90 | PTGER1 (0.49) | SLC22A12PTGER1 | |
| SCHEMBL7744756 | 0.89 | SLC22A12 (0.47) | SLC22A12PTGER1 | |
| SCHEMBL7744400 | 0.88 | SLC22A12 (0.51) | SLC22A12PTGER1 | |
| SCHEMBL7744750 | 0.87 | SLC22A12 (0.48) | SLC22A12PTGER1 | |
| SCHEMBL7744713 | 0.84 | KMT2A (0.62) | PTGER1 | |
| SCHEMBL1137143 | 0.82 | PTGER1 (0.59) | PTGER1 | |
| SCHEMBL7744403 | 0.81 | MEN1 (0.66) | PTGER1 | |
| SCHEMBL18295022 | 0.81 | PTGER1 (0.64) | PTGER1 | |
| SCHEMBL1899144 | 0.80 | AURKA (0.56) | PTGER1 | |
| SCHEMBL2077298 | 0.78 | MEN1 (0.62) | PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | claimed |
| EP-1252156-A1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | University College London (GB) | 2002-10-30 | — | — | EP | claimed |
| WO-2001057024-A1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2001-08-09 | — | — | WO | claimed |
| US-7790761-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2010-09-07 | — | — | US | disclosed |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | GARTHWAITE GITI | 2006-05-11 | — | — | US | disclosed |
| US-7009056-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2006-03-07 | — | — | US | disclosed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | CACNA1F, SCNN1B, CACNA1B | SLC22A12 359/4885PTGER1 1081/4885 |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | CACNA1I, CACNA1F, CACNA1C | SLC22A12 424/4885PTGER1 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.